Metacrine, a Phase 1 biotech developing FXR agonist therapies for NASH, raised $85 million by offering 6.5 million shares at $13, within the range of $12 to $14. At pricing, the company commands a fully diluted market value of $364 million.
Metacrine plans to list on the Nasdaq under the symbol MTCR. Jefferies, Evercore ISI and RBC Capital Markets acted as lead managers on the deal.
NASH biotech Metacrine prices IPO at $13 midpoint
September 16, 2020

